Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 7
Submit an article Journal homepage
458
Views
75
CrossRef citations to date
0
Altmetric
Reviews

Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators

Pernille Nordly Faculty of Pharmaceutical Sciences, University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, DK-2100 Copenhagen O, Denmark + 45 35 33 64 02; + 45 35 33 60 30; [email protected]
, MSc PhD,
Henriette Baun Madsen Faculty of Pharmaceutical Sciences, University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, DK-2100 Copenhagen O, Denmark + 45 35 33 64 02; + 45 35 33 60 30; [email protected]
, MSc Pharm PhD,
Hanne Moerck Nielsen Faculty of Pharmaceutical Sciences, University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, DK-2100 Copenhagen O, Denmark + 45 35 33 64 02; + 45 35 33 60 30; [email protected]
, MSc Pharm PhD &
Camilla Foged Faculty of Pharmaceutical Sciences, University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry, Universitetsparken 2, DK-2100 Copenhagen O, Denmark + 45 35 33 64 02; + 45 35 33 60 30; [email protected]
, MSc PhD
Pages 657-672 | Published online: 19 Jun 2009

Bibliography

  • Schijns VEJC, Degen WGJ. Vaccine immunopotentiators of the future. Clin Pharmacol Ther 2007;82(6):750-5
  • Eickhoff TC, Myers M. Workshop summary: aluminum in vaccines. Vaccine 2002;20:S1-4
  • Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Rev Immunol 2005;6(1):17-21
  • Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989;54(Pt 1):1-13
  • Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388(6640):394-7
  • Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4(7):499-511
  • Cella M, Salio M, Sakakibara Y, et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999;189(5):821-9
  • Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002;296(5566):298-300
  • Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004;41(11):1099-108
  • Pancer Z, Cooper MD. The evolution of adaptive immunity. Annu Rev Immunol 2006;24:497-518
  • Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24(6):677-88
  • Squier MK, Cohen JJ. Cell-mediated cytotoxic mechanisms. Curr Opin Immunol 1994;6(3):447-52
  • Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76(2):287-99
  • Janeway CA Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994;76(2):275-85
  • Zinkernagel RM. Immunology taught by viruses. Science 1996;271(5246):173-8
  • Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine 2002;20(Suppl 5):B10-B16
  • Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc Soc Exp Biol Med 1937;37(3):509-13
  • Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1(1):111-8
  • Miles AP, McClellan HA, Rausch KM, et al. Montanide((R)) ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005;23(19):2530-9
  • Toledo H, Baly A, Castro O, et al. A phase I clinical trial of a mufti-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001;19(30):4328-36
  • Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999;17(23-24):3145-59
  • Ott G, Barchfeld GL, Chernoff D, et al. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995;6:277-96
  • Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 (TM) adjuvant. Vaccine 2008;26(26):3209-22
  • Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001;19(17-19):2673-80
  • Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008;22(5):279-92
  • Liang MT, Davies NM, Blanchfield JT, Toth I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv 2006;3(4):379-88
  • Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 1997;240(3):793-7
  • Foged C, Arigita C, Sundblad A, et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22(15-16):1903-13
  • Vangasseri DP, Cui ZR, Chen WH, et al. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 2006;23(5):385-95
  • Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm 2008;5(3):464-71
  • Gregoriadis G, McCormack B, Obrenovic M, et al. Vaccine entrapment in liposomes. Methods 1999;19(1):156-62
  • Nakanishi T, Hayashi A, Kunisawa J, et al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur J Immunol 2000;30(6):1740-7
  • Owais M, Gupta CM. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000;267(13):3946-56
  • Ahmad N, Masood AK, Owais M. Fusogenic potential of prokaryotic membrane lipids – Implication in vaccine development. Eur J Biochem 2001;268(22):5667-75
  • Stewart VA, McGrath SM, Walsh DS, et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006;24(42-43):6483-92
  • Vandepapeliere P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008;26(10):1375-86
  • Joseph A, Itskovitz-Cooper N, Samira S, et al. A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 2006;24(18):3990-4006
  • Brunel F, Darbouret A, Ronco J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine 1999;17(17):2192-203
  • Pialoux G, Hocini H, Perusat S, et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine 2008;26(21):2657-66
  • Agger EM, Rosenkrands I, Hansen J, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 2008;3(9):e3116 pages 1-10
  • Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23(27):6674-81
  • Sangha R, Butts C. L-BLP25: A peptide vaccine strategy in non-small cell lung cancer. Clin Cancer Res 2007;13(15):4652S-U3
  • Morein B, Sundquist B, Hoglund S, et al. Iscom, a novel structure for antigenic presentation of membrane-proteins from enveloped viruses. Nature 1984;308(5958):457-60
  • Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996;74(1):8-25
  • Sanders MT, Brown LE, Deliyannis G, Pearse MJ. ISCOM (TM)-based vaccines: the second decade. Immunol Cell Biol 2005;83(2):119-28
  • Cox JC, Sjolander A, Barr IG. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998;32(3):247-71
  • Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004;23(2):172-81
  • Davis ID, Chen WS, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8 + T cell responses in humans. Proc Natl Acad Sci USA 2004;101(29):10697-702
  • Sjolander A, Vantland B, Bengtsson KL. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 1997;177(1):69-76
  • Sjolander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 1998;64(6):713-23
  • McBurney WT, Lendemans DG, Myschik J, et al. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine 2008;26(35):4549-56
  • Kirkby NS, Samuelsen PB. Composition for vaccination. US20060147509; 2006
  • Pearse MJ, Drane D. ISCOMATRIX((R)) adjuvant for antigen delivery. Adv Drug Deliv Rev 2005;57(3):465-74
  • Bengtsson KL, Sjolander A. Adjuvant activity of iscoms; Effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 1996;14(8):753-60
  • Ennis FA, Cruz J, Jameson J, et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999;259(2):256-61
  • Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM(TM) vaccines and conventional vaccines. Vaccine 2000;19(9-10):1180-7
  • Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007;5(7):505-17
  • Gay NJ, Gangloff M. Structure and function of toll receptors and their ligands. Annu Rev Biochem 2007;76:141-65
  • Agrawal S, Agrawal A, Doughty B, et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003;171(10):4984-9
  • Klein S, Barchet W, Schnurr M, et al. Combined vaccination using TLR-9 ligands and ISCOMATRIX/antigen in a novel murine model of autochthonous liver tumors. Wien Klin Wochenschr 2008;120:93-93
  • Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Exp Rev Vaccines 2007;6(5):723-39
  • Brandt L, Elhay M, Rosenkrands I, et al. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000;68(2):791-5
  • Eriksson EMY, Jackson DC. Recent advances with TLR2-targeting lipopeptide-based vaccines. Curr Protein Pept Sci 2007;8(4):412-7
  • Babu JS, Nair S, Kanda P, Rouse BT. Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. Vaccine 1995;13(17):1669-76
  • Zaks K, Jordan M, Guth A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006;176(12):7335-45
  • Jaafari MR, Badiee A, Khamesipour A, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007;25(32):6107-17
  • Joseph A, Louria-Hayon I, Plis-Finarov A, et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002;20(27-28):3342-54
  • Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004;172(11):6545-9
  • Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11(3):263-70
  • Song XT, Evel-Kabler K, Rollins L, et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. Plos Med 2006;3(1):76-93
  • Moreira LO, Smith AM, DeFreitas AA, et al. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 2008;26(46):5808-13
  • Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17(11):1075-81
  • Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000;12(4):456-63
  • Cox JC, Coulter AR. Adjuvants – A classification and review of their modes of action. Vaccine 1997;15(3):248-56
  • O'Hagan DT, MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001;18(3):69-85
  • Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998;10(5):349-50
  • Schijns VEJC, Degen WGJ. Vaccine immunopotentiators of the future. Clin Pharmacol Ther 2007;82(6):750-5
  • Zinkernagel RM, Ehl S, Aichele P, et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997;156:199-209
  • Karrer U, Althage A, Odermatt B, et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J Exp Med 1997;185(12):2157-70
  • Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52
  • Jiang W, Swiggard WJ, Heufler C, et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 1995;375(6527):151-5
  • Xiang SD, Scholzen A, Minigo G, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 2006;40(1):1-9
  • Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005;298(2):315-22
  • Seubert A, Monaci E, Pizza M, et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008;180(8):5402-12
  • Schijns VE. Induction and direction of immune responses by vaccine adjuvants. Crit Rev Immunol 2001;21(1-3):75-85
  • Kim JJ, Bagarazzi ML, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997;15(7):641-6
  • Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants. Biotherapy 1994;7(3-4):261-9
  • Matzinger P. The danger model: a renewed sense of self. Science 2002;296(5566):301-5
  • Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
  • Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5(11):1249-55
  • Goto N, Kato H, Maeyama J, et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 1997;15(12-13):1364-71
  • Lascelles AK, Eagleson G, Beh KJ, Watson DL. Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet Immunol Immunopathol 1989;22(1):15-27
  • Freund J. The mode of action of immunologic adjuvants. Adv Tuberc Res 1956;7:130-47
  • Bangman AD, Horne RW, Glauert AM, et al. Action of saponins on biological membranes. Nature 1962;196:952-5
  • van Binnendijk RS, van Baalen CA, Poelen MC, et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J Exp Med 1992;176(1):119-28
  • Boyce TG, Hsu HH, Sannella EC, et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 2000;19(2-3):217-26
  • Hu KF, Elvander M, Merza M, et al. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 1998;113(2):235-43
  • Aguila A, Donachie AM, Peyre M, et al. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 2006;24(24):5201-10
  • Carol H, Nieto A, VillacresEriksson M, Morein B. Intranasal immunization of mice with Echinococcus granulosus surface antigens Iscoms evokes a strong immune response, biased towards glucidic epitopes. Parasite Immunol 1997;19(5):197-205
  • Carol H, Nieto A. A mucosal IgA response, but no systemic antibody response, is evoked by intranasal immunisation of dogs with Echinococcus granulosus surface antigens iscoms. Vet Immunol Immunopathol 1998;65(1):29-41
  • Brennan FR, Bellaby T, Helliwell SM, et al. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J Virol 1999;73(2):930-8
  • Furrie E, Smith RE, Turner MW, et al. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 2002;20(17-18):2254-62
  • Mowat AM, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993;80(4):527-34
  • Childers NK, Miller KL, Tong G, et al. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun 2000;68(10):5509-16
  • Khatri K, Goyal AK, Gupta PN, et al. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008;26(18):2225-33
  • Heurtault B, Gentine P, Thomann JS, et al. Design of a liposomal candidate vaccine against pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity. Pharm Res 2009;26(2):276-85
  • Chin J, San Gil F. Skin delivery of a hybrid liposome/ISCOM vaccine implicates a role for adjuvants in rapid modulation of inflammatory cells involved in innate immunity before the enhancement of adaptive immune responses. Immunol Cell Biol 1998;76(3):245-55
  • Mishra D, Mishra PK, Dubey V, et al. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008;33(4-5):424-33
  • Wang J, Hu JH, Li FQ, et al. Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA-cationic deformable liposome complex. Exp Dermatol 2007;16(9):724-9
  • O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003;2(9):727-35
  • van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000;165(9):4778-82
  • Villadangos JA, Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007;7(7):543-55

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.